Company intelligence / Profile preview

OncoC4

Rockville, Maryland, USAoncoc4.com ↗

Ownership: Private
Development stage: Phase 3

Overview

OncoC4’s lead candidate ONC‑392/gotistobart has advanced to late-stage clinical trials for solid tumors. The company has a strategic partnership with BioNTech for co-development and commercialization of ONC‑392. Early data suggest the approach may enhance anti-tumor activity while reducing autoimmune side effects compared to earlier CTLA‑4 inhibitors. Additional programs are advancing through preclinical and early clinical development targeting novel pathways such as PD‑1/VEGF bispecifics and Siglec agonists.

Therapeutic areas: OncologyNeurology
Modalities: monoclonal antibodies (mAbs)bispecific antibodies (BsAbs)antibody-drug conjugates (ADCs)CAR T-cell therapies
Industry: Biotech

Drug pipeline

13 assets

covid-19 antibody nasal spray

12 more assets in the full pipeline.

Request access →

Partnerships

BioNTech – exclusive worldwide license/co-development agreement for ONC–392/BNT316 ($200M upfront plus milestones & royalties)

Beyond the preview

Go deeper on OncoC4.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoC4.

Explore the full profile